You do not currently have permission to view the full text for this document. Please sign in to an account with an active subscription or contact support.
This fourth issue of Neuro-Psychoanalysis features an unprecedented interdisciplinary dialogue on the fascinating topic of confabulation, involving leading neuroscientific and psychoanalytic experts. Also of considerable interest in this issue are the continuing discussions of paper (Vol. 1, no. 2, 1999) on the neuropsychology of dreaming and Paul Whittle's paper in the same issue on experimental psychology and psychoanalysis. Readers are encouraged to participate in all these ongoing discussions, and to submit commentaries on the original articles by Yovell and Watt, published in this issue. These discussions take place via our website (neuro-psa.com) which functions as an electronic supplement to the journal.
Our website is also of interest in its own right. We have recently inaugurated a new page devoted to online discussion of clinical matters (click on <clinical forum>). The current discussion revolves around a contribution by Birgit Borg Mathiesen on the assessment of frontal lobe dysfunction. Visitors to the website can also register online for the Second International Neuro-Psychoanalysis Congress to be held in New York in April 2001, and apply for founding membership of the International Society for Neuro-Psychoanalysis Society (see Bulletin at the back of this issue).
We are pleased to announce that Neuro-Psychoanalysis has been designated the official organ of the International Neuro-Psychoanalysis Society. Our Regional Bulletins section will be incorporated into the Society's Bulletin.
The next issue of the journal will be organized around an article by the eminent Italian neuropsychologist Carlo Semenza, on the theoretical and methodological relationship between psychoanalysis and cognitive neuropsychology.
Neuro-Psychoanalysis publishes unsolicited papers on any topic that can facilitate consilience between psychoanalysis and neuroscience. Empirical (i.e., clinical and experimental) contributions will receive due promin